"Just when you got used to it: Updates to Hydroxychloroquine Screening Guidelines for 2026" by Dr. Michelle Abou-Jaoude

 

Learning Objectives: 

  • Recognize hydroxychloroquine toxicity across multimodal imaging at different stages toxicity
  • Describe the changes to the standard screening modalities from the last guidelines in 2016
  • Demonstrate comfortably knowing how and when to screen patients on hydroxychloroquine

 

Pre-Presentation Question: 

  1. Which of the following is NOT a risk factor for developing hydrochloroquine toxicity? 
    1. Higher dose and duration
    2. Age at the time of starting treatment
    3. Kidney Disease
    4. Liver Disease
    5. Tamoxifen use
  2. Which visual fields should we use to screen for HCQ toxicity?
    1. 10-2 for everybody!
    2. 24-2 for everybody!
    3. 10-2 for those of European and middle-eastern descent, 30-2 for east Asian descent
    4. 10-2 and 30-2 for everybody, or new modified 24-2C protocol
  3. Which of the following is not part of primary and secondary techniques for screening for HCQ toxicity?
    1. Time domain OCT
    2. Wide-pattern Fundus auto-fluorescence
    3. Appropriate visual fields
    4. Multifocal ERG
Session date: 
03/06/2026 - 8:30am EST to 05/05/2026 - 11:59am EDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This Live activity is designated for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.
Faculty List: 

Michelle Abou-Jaoude, MD

has a financial relationship (Grant Or Contract) with Inflammasome;.